**Supplementary Table 2**. Chi-square results comparing the average monthly proportion of one-month paliperidone palmitate (PP1) to three-month paliperidone palmitate (PP3) switches between study epochs. Reported as total number of events (N) and percentage (%).

|  |  |  |  |
| --- | --- | --- | --- |
| **Epoch A** | **Epoch B** | **PP1 to PP3 Switches** | **PP3 to PP1 Switches** |
| **Epoch A, N (%)** | **Epoch B, N (%)** | **P-value** | **Epoch A, N (%)** | **Epoch B, N (%)** | **P-value** |
| Pre-COVID Comparator Period(Mar - May 2019) | Primary COVID Escalation Period(Mar - May 2020) | 147.33(4.26%) | 140.00(4.02%) | 0.62 | 18.33(2.12%) | 16.00(1.36%) | 0.19 |
| Pre-COVID Comparator Period(Mar - May 2019) | Second COVID Escalation Period(Sept - Nov 2020) | 147.33(4.26%) | 100.33(2.82%) | **<0.01** | 18.33(2.12%) | 19.67(1.54%) | 0.32 |
| Primary COVID Escalation Period(Mar - May 2020) | COVID Maintenance Period(Jun - Aug 2020) | 140.00(4.02%) | 88.33(2.53%) | **<0.01** | 16.00(1.36%) | 18.67(1.52%) | 0.74 |
| COVID Maintenance Period(Jun - Aug 2020) | Second COVID Escalation Period(Sept - Nov 2020) | 88.33(2.53%) | 100.33(2.82%) | 0.46 | 18.67(1.52%) | 19.67(1.54%) | 0.97 |
| Primary COVID Escalation Period(Mar - May 2020) | Second COVID Escalation Period(Sept - Nov 2020) | 140.00(4.02%) | 100.33(2.82%) | **<0.01** | 16.00(1.36%) | 19.67(1.54%) | 0.71 |
| Pre-COVID Comparator Period(Mar - May 2019) | COVID Awareness Period(Dec 2019 - Feb 2020) | 147.33(4.26%) | 102.67(3.03%) | **<0.01** | 18.33(2.12%) | 21.33(1.97%) | 0.82 |